Pharma Voice102d agoneutral
What’s at stake in Amgen’s showdown with the FDA?The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the large pharma is digging its heels in.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
40last 24h
1793last 7d
300● bullish (7d)
170● bearish (7d)
205publishers
MT Newswires103d agoneutral
Sector Update: Health Care Stocks Softer in Afternoon TradingHealth care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H
Quartz103d agoneutral
Amgen invests $300M more in Puerto Rico biologics plantThe additional investment builds on $650 million Amgen committed to its Juncos facility last year, which supplies medicines to more than 60 countries
24/7 Wall St.103d agoneutral
Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
Zacks103d agoneutral
3 Top Dividend Stocks to Maximize Your Retirement IncomeThe traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.